Comparison of interleukin-1 beta expression by in situ hybridization in monoclonal gammopathy of undetermined significance and multiple myeloma.

We investigated whether interleukin-1beta (IL-1beta) is differentially expressed in plasma cells from monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM) patients because IL-1beta appears to play a major role in the development of lytic bone lesions, the major clinical feature distinguishing MGUS from myeloma. In situ hybridization (ISH) for IL-1beta was performed using bone marrow aspirates from 51 MM, 7 smoldering MM, 21 MGUS, and 5 normal control samples. Using the ISH technique IL-1beta mRNA was detectable in the plasma cells from 49 of 51 patients with active myeloma and 7 of 7 patients with smoldering myeloma. In contrast, 5 of 21 patients with MGUS and 0 of 5 normal controls had detectable IL-1beta message. Bone lesions were present in 40 of the 51 MM patients analyzed, and all 40 patients had IL-1beta mRNA by ISH. These results show that greater than 95% of MM patients but less than 25% of MGUS patients are positive for IL-1beta production. In the future, continued follow-up of IL-1beta positive and negative MGUS patients should determine whether aberrant expression of plasma cell IL-1beta is predictive of those MGUS patients that will eventually progress to active myeloma.

[1]  R. Kyle,et al.  Monoclonal gammopathies of undetermined significance. , 2002, Reviews in clinical and experimental hematology.

[2]  G. Ahmann,et al.  Contrast in cytokine expression between patients with monoclonal gammopathy of undetermined significance or multiple myeloma , 1998, Leukemia.

[3]  J. Said,et al.  Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients. , 1997, Science.

[4]  A. Velázquez,et al.  Transcriptional induction of multiple cytokines by human respiratory syncytial virus requires activation of NF-kappa B and is inhibited by sodium salicylate and aspirin. , 1997, Virology.

[5]  P. Corley.  Induction of interleukin-1 and glucocorticoid hormones by HIV promotes viral replication and links human chromosome 2 to AIDS pathogenesis: genetic mechanisms and therapeutic implications. , 1997, Medical hypotheses.

[6]  S. Dower,et al.  Modulation of osteoclast-activating factor activity of multiple myeloma bone marrow cells by different interleukin-1 inhibitors. , 1996, Experimental hematology.

[7]  C. Dinarello,et al.  Biologic basis for interleukin-1 in disease. , 1996, Blood.

[8]  A. Beaulieu,et al.  Epstein-Barr virus modulates de novo protein synthesis in human neutrophils. , 1995, Blood.

[9]  Greipp Pr,et al.  Pathogenetic relation between monoclonal gammopathies of undetermined significance and multiple myeloma. , 1995 .

[10]  J. Lust.  Role of cytokines in the pathogenesis of monoclonal gammopathies. , 1994, Mayo Clinic proceedings.

[11]  I. Franklin,et al.  Surface antigen expression of human neoplastic plasma cells includes molecules associated with lymphocyte recirculation and adhesion , 1991, British journal of haematology.

[12]  J. Drach,et al.  Expression of the neural cell adhesion molecule (CD56) by human myeloma cells , 1991, Clinical and experimental immunology.

[13]  I. Weissman,et al.  Evidence for a role of the integrin VLA-4 in lympho-hemopoiesis , 1991, The Journal of experimental medicine.

[14]  T. Grogan,et al.  Plasma cells in multiple myeloma express a natural killer cell- associated antigen: CD56 (NKH-1; Leu-19) , 1990 .

[15]  A. Carter,et al.  The role of interleukin‐1 and tumour necrosis factor‐α in human multiple myeloma , 1990 .

[16]  P. Greenberg,et al.  Hematopoietic progenitor cell expression of the H-CAM (CD44) homing-associated adhesion molecule. , 1990, Blood.

[17]  H. Asaoku,et al.  Production of interleukin 1 beta, a potent bone resorbing cytokine, by cultured human myeloma cells. , 1989, Cancer research.

[18]  A. Celeste,et al.  Using Synthetic Oligonucleotides as Probes , 1988, Current protocols in molecular biology.

[19]  R. Kyle,et al.  Smoldering multiple myeloma. , 1980, The New England journal of medicine.

[20]  M. Corbellino,et al.  Kaposi’s Sarcoma–Associated Herpesvirus Infection and Multiple Myeloma , 1997 .

[21]  P. Wingo,et al.  Cancer statistics, 1996 , 1996, CA: a cancer journal for clinicians.

[22]  P. Greipp,et al.  Pathogenetic relation between monoclonal gammopathies of undetermined significance and multiple myeloma. , 1995, Stem cells.

[23]  R A Kyle,et al.  "Benign" monoclonal gammopathy--after 20 to 35 years of follow-up. , 1993, Mayo Clinic proceedings.

[24]  P. Sehgal,et al.  Expression of retrovirally transduced IL-1 alpha in IL-6-dependent B cells: a murine model of aggressive multiple myeloma. , 1991, Growth factors.

[25]  T. Grogan,et al.  Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19). , 1990, Blood.

[26]  P. Lansdorp,et al.  Production of interleukin-1 by bone marrow myeloma cells. , 1989, Blood.

[27]  J. Berenson,et al.  Production of cytokines by bone marrow cells obtained from patients with multiple myeloma. , 1989, Blood.

[28]  P. Magee,et al.  Inhibition of 1,2-dimethylhydrazine-induced colon tumorigenesis in Balb/c mice by dehydroepiandrosterone. , 1984, Carcinogenesis.